For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $32.62 in the prior trading day, Surgery Partners Inc (NASDAQ: SGRY) closed at $32.26, down -1.10%. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 0.58 million shares were traded. SGRY stock price reached its highest trading level at $32.7 during the session, while it also had its lowest trading level at $32.02.
Ratios:
Our goal is to gain a better understanding of SGRY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.09. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 1.83. In the meantime, Its Debt-to-Equity ratio is 1.76 whereas as Long-Term Debt/Eq ratio is at 1.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Macquarie on June 28, 2024, initiated with a Outperform rating and assigned the stock a target price of $31.
On March 06, 2024, Barclays started tracking the stock assigning a Equal Weight rating and target price of $35.
TD Cowen Upgraded its Market Perform to Outperform on November 14, 2023, whereas the target price for the stock was revised from $39 to $35.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’24 when Bradley Owens bought 9,241 shares for $30.69 per share.
Bane Harrison R. sold 6,325 shares of SGRY for $196,742 on Sep 04 ’24. The National Group President now owns 48,236 shares after completing the transaction at $31.11 per share. On Sep 04 ’24, another insider, Harrison Bane, who serves as the Officer of the company, bought 6,325 shares for $31.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 4101019904 and an Enterprise Value of 8932841472. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.42 while its Price-to-Book (P/B) ratio in mrq is 2.10. Its current Enterprise Value per Revenue stands at 3.092 whereas that against EBITDA is 15.519.
Stock Price History:
Over the past 52 weeks, SGRY has reached a high of $36.92, while it has fallen to a 52-week low of $22.05. The 50-Day Moving Average of the stock is 6.23%, while the 200-Day Moving Average is calculated to be 11.07%.
Shares Statistics:
The stock has traded on average 1.12M shares per day over the past 3-months and 783110 shares per day over the last 10 days, according to various share statistics. A total of 126.59M shares are outstanding, with a floating share count of 70.88M. Insiders hold about 44.25% of the company’s shares, while institutions hold 68.84% stake in the company. Shares short for SGRY as of 1724976000 were 10831908 with a Short Ratio of 8.88, compared to 1722384000 on 10949625. Therefore, it implies a Short% of Shares Outstanding of 10831908 and a Short% of Float of 18.75.
Earnings Estimates
Its stock is currently analyzed by 12.0 different market analysts. The consensus estimate for the next quarter is $0.48, with high estimates of $0.63 and low estimates of $0.37.
Analysts are recommending an EPS of between $1.28 and $0.88 for the fiscal current year, implying an average EPS of $1.06. EPS for the following year is $1.27, with 12.0 analysts recommending between $1.59 and $0.87.
Revenue Estimates
11 analysts predict $769.82M in revenue for the current quarter. It ranges from a high estimate of $780.59M to a low estimate of $757.9M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $672.27MFor the next quarter, 11 analysts are estimating revenue of $836.3M. There is a high estimate of $852.21M for the next quarter, whereas the lowest estimate is $829.39M.
A total of 12 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.11B, while the lowest revenue estimate was $3.08B, resulting in an average revenue estimate of $3.09B. In the same quarter a year ago, actual revenue was $2.74BBased on 12 analysts’ estimates, the company’s revenue will be $3.38B in the next fiscal year. The high estimate is $3.43B and the low estimate is $3.32B.
